[N:1]1([C:7]([C:9]2[C:13]3[CH2:14][N:15](C(OC(C)(C)C)=O)[CH2:16][CH2:17][C:12]=3[O:11][N:10]=2)=[O:8])[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1.Cl>CO>[N:1]1([C:7]([C:9]2[C:13]3[CH2:14][NH:15][CH2:16][CH2:17][C:12]=3[O:11][N:10]=2)=[O:8])[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1tert-Butyl 3-(piperidine-1-carbonyl)-6,7-dihydroisoxazolo[4,5-c]pyridine-5(4H)-carboxylate (0.3 g, 0.89 mmol) (product of stage 6) was dissolved in 7 ml of methanol, concentrated HCl (0.56 ml, 17.8 mmol) was added and the mixture was stirred at room temperature overnight. The solvent was then distilled off in vacuo, the residue was taken up in NaHCO3 solution and the mixture was extracted with ethyl acetate. The combined organic phases were dried with MgSO4, filtered and concentrated in vacuo. The crude product was employed in the next stage without further purification.
Loading…